Overview

Insulin like growth factor 2 (IGF2) is a gene that encodes a protein that functions in development and growth. Missense mutations, synonymous mutations, frameshift insertions, and frameshift deletions are observed in cancers such as stomach cancer, colon cancer, and skin cancer.

IGF2 is altered in 0.69% of all cancers with colon adenocarcinoma, lung adenocarcinoma, endometrial endometrioid adenocarcinoma, cutaneous melanoma, and rectal adenocarcinoma having the greatest prevalence of alterations [3].

The most common alterations in IGF2 are IGF2 Loss (0.14%), IGF2 Amplification (0.11%), IGF2 T163P (1.05%), IGF2 A19T (0.01%), and IGF2 E147K (0.03%) [3].

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.